Catalog No.: PC-42933Not For Human Use, Lab Use Only.
CB-839 (Telaglenastat) is a potent, selective, and orally bioavailable inhibitor of glutaminase with IC50 of 28 and 23 nM for glutaminase-1 (GLS1) in kidney and brain (GAC and KGA), but not the liver form of glutaminase (GLS2, IC50>1 uM).
CB-839 (Telaglenastat) is a potent, selective, and orally bioavailable inhibitor of glutaminase with IC50 of 28 and 23 nM for glutaminase-1 (GLS1) in kidney and brain (GAC and KGA), but not the liver form of glutaminase (GLS2, IC50>1 uM).
CB-839 (Telaglenastat) demonstrates antiproliferative activity in triple-negative breast cancer (TNBC) cell line HCC-1806 and MDA-MB-231 with IC50 of 20-55 nM.
CB-839 (Telaglenastat) decreases glutamine consumption, glutamate production, oxygen consumption, and the steady-state levels of glutathione and several tricarboxylic acid cycle intermediates.
CB-839 (Telaglenastat) exhibits vivo efficacy in breast cancer xenograft models, both as a single agent and in combination with paclitaxel.
